As the authors also cited, there was a preceding study by Ho et al. (2017, Biochem. Biophys. Res. Commun.) that YY1AP1 upregulation was significantly associated with the overall survival (OS) of colorectal adenocarcinoma patients. With other examples in different cancers, the authors investigated the clinical specimens and demonstrated YY1AP1’s potential as a prognostic biomarker in gastric cancer. Although additional studies by the other groups would also be necessary to prove (because the differences may not be striking depending on the categories shown in figures 2 and 4), the OS between YY1AP1-high and -low were 56.0±3.0 and 67.4±2.4 (months), respectively (p=0.014). The 5-year OS was significantly different between the two groups (YY1AP1-high: 48.4% and YY1AP1-low: 72.7%). Thus, YY1AP1 may be a new prognostic marker. Mechanistically, the RNAi experiment clearly demonstrated the inverse correlation between YY1AP1 and p21Cip expression (The article did not clearly indicate p21Cip, so it may be harder to understand for non-experts). As a future direction, although not surprising, it would be interesting to know how YY1AP1 affects YAP signaling pathway in gastric cancer.